This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Tekla Life Sciences Investors
HQL : NYSE : Financial
$18.04 up0.01 | 0.06%
Today's Range: 17.96 - 18.17
Avg. Daily Volume: 67,400
05/05/16 - 4:02 PM ET


HQL Peer Plot Chart

This chart compares HQL to the highest rated funds in its peer group of Sector - Health/Biotechnology funds. The above graph illustrates two key measures that investors should consider when assessing the investment potential of a particular fund. One of the key factors is how the fund has performed over the most recent reporting period, defined as the 1 year total return on the bottom axis. The second factor is the fund's reported expense ratio, on the right axis, which includes things like management fees. The best funds, with higher returns and lower expenses, stake out a position in the lower left part of this graph.

TOP RATED FUNDS : Sector - Health/Biotechnology
1 Year
3 Year
iShares US Medical Devices ETF IHI 1.09 5.91 18.97 0.43 1
iShares US Healthcare Providers ETF IHF -1.06 -6.91 16.86 0.43 2
Health Care Select Sector SPDR XLV -4.50 -2.92 15.77 0.15 3
Vanguard HealthCare Index ETF VHT -5.66 -5.30 15.96 0.09 4
iShares US Healthcare ETF IYH -4.81 -4.46 15.47 0.43 5
BlackRock Health Sciences Trust BME -7.03 -0.83 19.86 1.11 6
iShares Global Healthcare IXJ -5.56 -5.65 12.25 0.47 7
Gabelli Healthcare & WellnessRx Tr GRX -1.54 -6.26 10.52 1.60 8
PowerShares Dynamic Pharmaceuticals PJP -12.39 -14.56 19.41 0.56 9
Tekla Life Sciences Investors HQL -19.87 -23.26 11.95 1.17 23
The above table compares the total return performance and expense ratio of Tekla Life Sciences Investors to the top rated funds within the Sector - Health/Biotechnology peer group. Tekla Life Sciences Investors ranks number 23 out of 31 Sector - Health/Biotechnology closed-end and exchange-traded funds that we rate.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs